<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713401</url>
  </required_header>
  <id_info>
    <org_study_id>CVT 4129</org_study_id>
    <nct_id>NCT00713401</nct_id>
  </id_info>
  <brief_title>Safety Study of Tecadenoson to Treat Atrial Fibrillation</brief_title>
  <official_title>An Open-Label, Sequential-Group, Dose-Escalation Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Tecadenoson Alone and in Combination With a Beta-Blocker in Adults With Rapid Atrial Fibrillation (CVT 4129)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels
      when given alone and in combination with a beta-blocker (esmolol) in patients with atrial
      fibrillation to control rapid heart rate. Explore the pharmacokinetic and pharmacodynamic
      effects when given alone and in combination with beta-blocker (esmolol).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities</measure>
    <time_frame>Baseline to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac parameters R-R interval and ventricular rate measured by electrocardiogram</measure>
    <time_frame>Baseline to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecadenoson</intervention_name>
    <description>Tecadenoson administered intravenously (i.v.)</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <other_name>CVT-510</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol low dose infusion according to manufacturer's instructions</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_label>Cohort E</arm_group_label>
    <other_name>Brevibloc®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of atrial fibrillation in need of treatment for rate control

          -  Be able and willing to abstain from any antiarrhythmics, including atrioventricular
             (AV) nodal blocking agents (except for esmolol per protocol), from no later than 8:00
             p.m. on the day prior to dosing until completion of the last dose period assessment

          -  Be able and willing to abstain from xanthine- or chocolate-containing foods,
             beverages, and medications

          -  Females must be post-menopausal or sterilized; or if of childbearing potential, must
             not be breastfeeding and must have a negative pregnancy test at screening and no
             intention of becoming pregnant during the course of the study. Males and females must
             be using adequate contraception during the study.

        Exclusion Criteria:

          -  Have a known accessory pathway

          -  Have active myocardial ischemia or recent acute coronary syndrome

          -  Have acute or overt heart failure, bradycardia, heart block greater than first degree,
             or cardiogenic shock

          -  Have allergies or contraindications to treatment with esmolol or aminophylline, or any
             of their constituents

          -  Have a supine cuff systolic blood pressure &lt; 90 mm Hg

          -  Be undergoing treatment with theophylline/aminophylline preparations, Trental®
             (pentoxifylline), or carbamazepine

          -  Have asthma or other reactive airways disease currently on-treatment

          -  Have a history of an active or chronic pancreatic disease or clinically significant
             increased levels of serum amylase or lipase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CV Therapeutics, Inc.</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2008</study_first_posted>
  <disposition_first_submitted>January 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2014</disposition_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
    <mesh_term>Tecadenoson</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

